Viatris To Shed OTC, APIs And Women’s Health As Biocon Deal Nears Completion
Expecting Further $5bn-$6bn In Pre-Tax Proceeds, As Two Acquisitions Announced
Viatris has marked an important inflection point in its short life, announcing several more planned divestitures alongside the proposed acquisition of a pair of eyecare companies for up to $750m in cash.
